Home » Stocks » ALDX

Aldeyra Therapeutics, Inc. (ALDX)

Stock Price: $13.37 USD 1.19 (9.73%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $13.00 -0.37 (-2.77%) Jan 15, 6:17 PM
Market Cap 473.03M
Revenue (ttm) n/a
Net Income (ttm) -39.42M
Shares Out 37.80M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $13.37
Previous Close $12.19
Change ($) 1.19
Change (%) 9.73%
Day's Open 12.36
Day's Range 12.31 - 13.60
Day's Volume 3,349,744
52-Week Range 1.62 - 13.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 day ago

The company announced the pricing of a public stock offering.

Business Wire - 1 day ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Business Wire - 2 days ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Business Wire - 1 week ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate ...

Business Wire - 1 week ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer's test results from the run-in cohort of...

Business Wire - 1 week ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line sy...

Business Wire - 3 weeks ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-infl...

Business Wire - 4 weeks ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administere...

Business Wire - 1 month ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company's senior management will participate in the following virtual investor c...

Seeking Alpha - 2 months ago

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeut...

Benzinga - 2 months ago

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst.  The Aldeyra Analyst: Kelly ...

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxa...

The Motley Fool - 2 months ago

An analyst is very bullish about the biotech stock.

Zacks Investment Research - 3 months ago

Is (ALDX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 months ago

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

Other stocks mentioned: KMPH, NERV, SAVA
Zacks Investment Research - 3 months ago

Is (ALDX) Outperforming Other Medical Stocks This Year?

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Zacks Investment Research - 4 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FLGT, NIU, PRIM, SURF
Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Seeking Alpha - 4 months ago

Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem

Seeking Alpha - 4 months ago

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, CDXC, CVX, HD, INTC, JNJ, MRK, NAD, VZ
Zacks Investment Research - 5 months ago

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 5 months ago

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of pati...

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the ...

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...

Zacks Investment Research - 6 months ago

Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 7 months ago

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ABBV, KZR
Seeking Alpha - 7 months ago

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on COVID-19 Development Update Conference Call - Transcript

Investors Business Daily - 7 months ago

Shares of Kindred Biosciences and Vaxart popped Wednesday after the drugmakers inked a manufacturing deal for a coronavirus vaccine tablet. Aldeyra is also planning to test a treatment.

Zacks Investment Research - 8 months ago

Aldeyra (ALDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 14th

Other stocks mentioned: ECOM, GLUU, HTGM
Zacks Investment Research - 8 months ago

Aldeyra Therapeutics Inc (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Aldeyra Therapeutics.

Seeking Alpha - 8 months ago

Aldeyra Therapeutics, Inc.'s (ALDX) CEO Dr.

Zacks Investment Research - 9 months ago

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 10 months ago

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2019 Results - Earnings Call Transcript

Market Watch - 1 year ago

Aldeyra Therapeutics Inc. shares ALDX, -6.14% rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results in the first part of a ...

Seeking Alpha - 1 year ago

Aldeyra Therapeutics Continues To Make Progress In Big Potential Markets Despite Stock Weakness

About ALDX

Aldeyra Therapeutics, a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small m... [Read more...]

Industry
Biotechnology
IPO Date
May 2, 2014
CEO
Dr. Todd C. Brady M.D., Ph.D.
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
ALDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is 26.60, which is an increase of 98.95% from the latest price.

Price Target
$26.60
(98.95% upside)
Analyst Consensus: Strong Buy